Home » Stocks » RLMD

Relmada Therapeutics, Inc. (RLMD)

Stock Price: $30.93 USD -0.23 (-0.74%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 495.62M
Revenue (ttm) n/a
Net Income (ttm) -29.99M
Shares Out 16.02M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $30.93
Previous Close $31.16
Change ($) -0.23
Change (%) -0.74%
Day's Open 31.24
Day's Range 30.30 - 32.26
Day's Volume 185,683
52-Week Range 28.40 - 54.00

More Stats

Market Cap 495.62M
Enterprise Value 361.53M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 16.02M
Float 14.65M
EPS (basic) -2.22
EPS (diluted) -2.22
FCF / Share -0.97
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.77M
Short Ratio 15.83
Short % of Float 12.10%
Beta 0.31
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.84
Revenue n/a
Operating Income -31.00M
Net Income -29.99M
Free Cash Flow -14.79M
Net Cash 134.09M
Net Cash / Share 8.37
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -158.57%
ROE -25.63%
ROIC -40.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$63.17*
(104.24% upside)
Low
40.0
Current: $30.93
High
75.0
Target: 63.17
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-12.73-6.92-7.22-16.22-17.10
Net Income-17.32-8.96-6.29-2.97-20.80
Shares Outstanding6.313.143.022.902.49
Earnings Per Share-2.74-2.86-2.08-1.04-8.36
Operating Cash Flow-10.50-6.00-6.47-13.14-16.23
Capital Expenditures--0.01-0.05-0.56-0.02
Free Cash Flow-10.50-6.01-6.52-13.71-16.25
Cash & Equivalents9.222.241.718.5022.47
Total Debt0.362.940.280.270.26
Net Cash / Debt8.85-0.701.438.2322.21
Assets10.223.052.8410.2424.39
Liabilities2.618.561.383.2015.58
Book Value7.61-5.511.467.048.81
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Relmada Therapeutics, Inc.
Country United States
Employees 6
CEO Sergio Traversa

Stock Information

Ticker Symbol RLMD
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: RLMD

Description

Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.